TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. The study is being conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform and will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.
TTX-MC138 is designed to target metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The trial's focus on patients with minimal residual disease addresses a critical unmet need, as these individuals have a high risk of recurrence despite standard curative treatments. The collaboration with Quantum Leap Healthcare Collaborative leverages the PRE-I-SPY platform, which is known for its adaptive trial design and ability to efficiently evaluate multiple therapies.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more information, visit the company's newsroom at https://ibn.fm/RNAZ.
The initiation of this Phase 2a trial marks a significant step in the development of TTX-MC138, potentially offering a new treatment option for colorectal cancer patients with minimal residual disease who currently have limited therapeutic strategies. The trial's results could provide insights into the role of microRNA-10b inhibition in preventing cancer recurrence and metastasis. For the full press release, visit https://ibn.fm/wuRri.
